Interestingly, it was proven that the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase 5 (ERK5) pathway, which is a target in many cancer therapies (increased expression reported in, e.g., melanoma), depends on importinA/B1 units, which opens new strategies for cancer therapy including IVM [74]. The gene discussed is WNK2; the disease is cancer.